Exagen (XGN) Enterprise Value (2018 - 2026)

Exagen (XGN) has 9 years of Enterprise Value data on file, last reported at -$21.5 million in Q1 2026.

• Quarterly Enterprise Value fell 92.18% year-over-year to -$21.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.5 million (down 92.18% YoY) and the FY2025 annual result came in at -$32.2 million, down 46.22% from the prior year.
• Enterprise Value rose to -$21.5 million in Q1 2026, from -$32.2 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$11.2 million in Q1 2025 to a low of -$89.8 million in Q1 2022.
• A 5-year average of -$39.5 million and a median of -$31.5 million in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2025 — Enterprise Value soared 58.95% — and 2026, when it sank 92.18%.
• Tracing XGN's Enterprise Value over 5 years: stood at -$62.4 million in 2022, then soared by 41.51% to -$36.5 million in 2023, then soared by 39.62% to -$22.0 million in 2024, then plunged by 46.22% to -$32.2 million in 2025, then jumped by 33.23% to -$21.5 million in 2026.
• The last three Enterprise Value figures came in at -$21.5 million (Q1 2026), -$32.2 million (Q4 2025), and -$35.7 million (Q3 2025), per Business Quant data.